Pharmacological values of medicinal mushrooms for prostate cancer therapy: The case of Ganoderma lucidum

Jamal Mahajna, Nesly Dotan, Ben Zion Zaidman, Roumyana D. Petrova, Solomon P. Wasser

Research output: Contribution to journalReview articlepeer-review

Abstract

Prostate cancer (PCa) is the most common male malignancy in many Western countries. Primary PCa is hormone dependent and is manageable by hormonal therapy. However, it rapidly develops to hormone-refractory tumors due to the accumulation of mutations in the androgen receptor and/or the acquisition of alternative cellular pathways that support proliferation and inhibit apoptosis of prostate cancer. To date, no effective therapy is available for clinically hormone-insensitive or hormone-refractory stages of prostate cancer.

Original languageEnglish
Pages (from-to)16-26
Number of pages11
JournalNutrition and Cancer
Volume61
Issue number1
DOIs
StatePublished - Jan 2009

ASJC Scopus subject areas

  • Nutrition and Dietetics
  • Oncology
  • Cancer Research
  • Medicine (miscellaneous)

Fingerprint

Dive into the research topics of 'Pharmacological values of medicinal mushrooms for prostate cancer therapy: The case of Ganoderma lucidum'. Together they form a unique fingerprint.

Cite this